Medication info
Telmidipin-Al Tablets 80/5/10 mg (Telmisartan, Amlodipine, Rosuvastatin)

Telmidipin-Al Tablets 80/5/10 mg (Telmisartan, Amlodipine, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Hana Pharm Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201803758 · Approved 2018.09.18 · Insurance code 657806300

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, slowing of atherosclerosis progression, and reduction of cardiovascular disease risk
Who takes it
Adults
Adult dose
Take 1 tablet of this medicine once daily with water, with or without food. It is recommended, if possible, to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients receiving a telmisartan/amlodipine combination and rosuvastatin as separate products, switching to this medicine (a combination product containing the same amounts of each active ingredient) may be considered for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or telmisartan 40 milligrams. - 80/5 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or this medicine 40/5 milligrams. - 40/10 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams. - 80/10 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or this medicine 40/10 milligrams. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. For patients with severe renal impairment, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 milligrams in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients 75 years of age or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and should continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Assessment of renal function should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 milligrams. The 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. The 40-milligram dose of rosuvastatin is contraindicated in some of these patients.

Ingredients

Manufacturer
Hana Pharm Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, slowing of atherosclerosis progression, and reduction of cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low levels of HDL-cholesterol
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients with essential hypertension who do not achieve adequate blood pressure control even with the administration of a combination of Telmisartan and Amlodipine. Additionally, Rosuvastatin is used as an adjunct in the treatment of primary hypercholesterolemia that is not controlled by diet and exercise and mixed hyperlipidemia. It helps to manage cholesterol levels in patients with familial hypercholesterolemia or dysbetalipoproteinemia and slows the progression of atherosclerosis. Especially in middle-aged and older patients with elevated high-sensitivity C-reactive protein levels and risk factors for cardiovascular disease, it reduces the risk of stroke, myocardial infarction, and arterial revascularization procedures. Therefore, this medication is used to improve cardiovascular health through blood pressure and lipid management.

How to take

Adult dose

Take 1 tablet of this medicine once daily with water, with or without food. It is recommended, if possible, to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients receiving a telmisartan/amlodipine combination and rosuvastatin as separate products, switching to this medicine (a combination product containing the same amounts of each active ingredient) may be considered for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or telmisartan 40 milligrams. - 80/5 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or this medicine 40/5 milligrams. - 40/10 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams. - 80/10 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or this medicine 40/10 milligrams. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. For patients with severe renal impairment, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 milligrams in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients 75 years of age or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and should continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Assessment of renal function should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 milligrams. The 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. The 40-milligram dose of rosuvastatin is contraindicated in some of these patients.

Precautions

This medication can cause serious harm to the fetus and newborn in pregnant women, so it must be discontinued immediately upon confirmation of pregnancy. This medication should not be administered to patients with hypersensitivity to its components or specific diseases, for example, those with a history of angioedema or severe liver or kidney impairment. Patients with severe hypotension, elderly patients, and those with hyperkalemia should use this medication cautiously, and special attention is also required for patients with impaired liver function. This medication may cause musculoskeletal side effects such as myalgia or muscle weakness, so if these symptoms occur, the patient should consult a healthcare provider immediately. Regular tests for liver function and serum creatine kinase (CK) levels should be conducted, and if abnormalities are found, the medication may need to be discontinued. As this medication may interact with other drugs, it is essential to inform the healthcare provider about any other medications being taken. Caution is necessary as dizziness or drowsiness may occur while driving or operating dangerous machinery. Women of childbearing potential should use appropriate contraception, and nursing mothers should avoid taking this medication or discontinue breastfeeding. This medication is not recommended for children as its safety has not been established, and elderly patients should start with a low dose and gradually increase it. In the case of overdose, symptoms such as hypotension and arrhythmias may occur, so immediate medical attention is necessary.

Side effects

Viral Upper Respiratory Tract Infection, Dyspnea, Hemorrhoids, Dyspepsia, Atopic Dermatitis, Peripheral Edema, Chronic Gastritis, Hiatal Hernia, Musculoskeletal Pain, Neck Pain, Rhinitis, Upper Abdominal Discomfort, Upper Abdominal Pain, Orthostatic Dizziness, Dysuria, Rhinosinusitis, Oro-pharyngeal Discomfort, Pulmonary Disease, Unspecified Intestinal Disease, Benign Gastrointestinal Neoplasm, Piles, Skeletal Pain, Osteoporosis, Sensory Loss, Movement Disorders, Atherosclerosis, Frequent Urination, Tinnitus, Hearing Loss, Halitosis, Fatty Liver, Upper Respiratory Infection, Low Back Pain, Sinusitis, Diarrhea, Pharyngitis, Erectile Dysfunction, Increased Sweating, Flushing, Fever, Leg Pain, Fatigue, Palpitations, Dependent Edema, Angina, Rapid Pulse, Leg Edema, Abnormal ECG, Insomnia, Drowsiness, Migraine, Sensory Disturbance, Involuntary Muscle Contractions, Flatulence, Constipation, Gastritis, Vomiting, Dry Mouth, Hemorrhoids, Gastroenteritis, Enteritis, Gastroesophageal Reflux, Toothache, Non-specific Gastrointestinal Disease, Gout, Hypercholesterolemia, Diabetes, Arthritis, Arthralgia, Leg Numbness, Anxiety, Depression, Neural Irritability, Infection, Fungal Infection, Abscess, Otitis Media, Asthma, Bronchitis, Rhinitis, Nosebleed, Dermatitis, Rash, Eczema, Pruritus, Angioedema, Erythema Multiforme, Urticarial Rash, Thrombocytopenia, Frequent Urination, Cystitis, Visual Disturbance, Conjunctivitis, Diplopia, Ocular Pain, Ear Pain, Weakness, Headache, Dizziness, Constipation, Nausea, Abdominal Pain, Pancreatitis, Pruritus, Rash, Hives, Myalgia, Myopathy, Rhabdomyolysis, Weakness, Angioedema, Thrombocytopenia, Jaundice, Hepatitis, Transaminase Elevation, Stevens-Johnson Syndrome, Eosinophilia with Systemic Symptoms Drug Reaction Syndrome, Lupus-like Syndrome, Muscle Rupture, Memory Loss, Peripheral Neuropathy, Cough, Thrombocytopenia, Hepatic Dysfunction, Syncope, Systemic Pain, Muscle Cramping, Gout, Erectile Dysfunction, Dizziness, Orthostatic Hypotension, Low Back Pain, Headache, Orthostatic Dizziness, Congestive Heart Failure, Hepatocellular Carcinoma, Cerebral Infarction, Upper Abdominal Discomfort, Orthostatic Dizziness, Serum Potassium Elevation, Hypotension, Anemia, Thrombocytopenia, Serum Creatinine Elevation, Acute Kidney Failure, Oliguria, Myalgia, Joint Pain, Sensory Disturbances, Chest Discomfort, Anorexia, Abdominal Distension, Abnormal Liver Function Tests, Numbness, Fatigue, Systemic Pain, Muscle Cramping

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a special container that does not let light in. Additionally, to maintain its effectiveness, it should be stored at room temperature, specifically between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.